FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular, to a therapeutic bifunctional agent that suppresses the expansion of cancer stem cells by blocking oncotic receptors CD47 and ERBB2. This agent consists of two fragments of VHH camelized antibodies, the first of which is able to recognize and selectively bind to CD47, and the second – to ERBB2. Fragments are linked together by a polypeptide linker (Gly4Ser)4 or another linker that allows VHH fragments to be space-separated in space in such a way as to ensure unhampered binding each of them to their protein target.
EFFECT: present invention makes it possible to increase the specificity, bioavailability, efficacy and selectivity of antibodies inhibiting the expansion of cancer stem cells, while reducing the effect on normal cells of the patient's body.
3 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SELECTIVE BIFUNCTIONAL DRUG ON THE BASIS OF FRAGMENTS OF CAMEL SINGLE-CHAIN ANTIBODIES, AIMED ON TUMOR RECEPTORS CD47/CD44, INTENDED FOR THERAPY OF MALIGNANT NEOPLASMS | 2016 |
|
RU2658764C1 |
| GENETIC CONSTRUCT CODING STRUCTURE OF T-CELL CHIMERIC RECEPTOR BASED ON SINGLE-CHAIN VHH ANTIBODIES SPECIFIC TO TUMOUR RECEPTOR CD47 FOR THE TARGETED IMMUNOTHERAPY OF MALIGNANT GROWTHS | 2017 |
|
RU2707535C2 |
| NK CELL LINE EXPRESSING PSMA-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND SECRETING CD47/SIRPA INTERACTION BLOCKER | 2020 |
|
RU2757353C1 |
| BISPECIFIC ANTI-HER2 / ANTI-HER3 ANTIBODIES | 2016 |
|
RU2653443C2 |
| COMPOSITIONS AND METHODS OF IMMUNOTHERAPY | 2014 |
|
RU2680010C2 |
| ANTIBODIES SPECIFIC TO CD47 AND PD-L1 | 2020 |
|
RU2779652C2 |
| BISPECIFIC BINDING AGENTS FOR MODULATING BIOLOGICAL ACTIVITY | 2005 |
|
RU2433831C2 |
| ANTIGEN RECEPTORS AND THEIR APPLICATIONS | 2018 |
|
RU2794945C2 |
| DIAGNOSTICS AND TREATMENT OF CANCER ASSOCIATED WITH CANCER STEM CELLS | 2014 |
|
RU2749867C2 |
| ANTIBODIES AGAINST CCR7 RECEPTOR FOR CANCER TREATMENT | 2006 |
|
RU2404808C2 |
